Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGS04
- Development stage
- Preclinical
- Lead developer
- Ignis Therapeutics
01
Overview
IGS04 is a preclinical-stage drug candidate being developed by Ignis Therapeutics for the treatment of treatment-resistant depression (TRD) and synaptopathies. As a CNS-focused therapeutic, it is designed to address conditions where standard treatments are ineffective. The specific molecular target and modality for IGS04 have not been publicly disclosed by Ignis Therapeutics, which focuses its pipeline on neurological and psychiatric disorders including epilepsy, Parkinson's disease, and depression. The program is part of the company's internal discovery and development efforts aimed at restoring synaptic function or addressing the underlying pathology of mood disorders.
Beyond the preview
Go deeper on IGS04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGS04.